Yeon Hee Park

This study is for people with a specific type of advanced breast cancer (HR+, HER2-) that has spread and has come back after they finished a prior course of hormone-blocking pills. It will test if adding a drug called ribociclib to standard hormone therapy (fulvestrant) works bet…